Show
Sort by
-
Outcome validation of a succinct HPV infection model for France
-
Treatment of actinic keratosis (AK) and basal cell carcinoma (BCC) with Metvix (R) (MAL-pdt) in real life practice: A cost of illness and model validation study
-
A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease
-
European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment
-
A multi-country health economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction
-
Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy - Implications for decision making
-
A cost-consequence analysis of darbepoetin alfa administered every 3 weeks (Q3W_DA) compared to weekly epoetin alfa (QW_EA) or epoetin beta (QW_EB) in patients with chemotherapy-induced anemia (CIA): A retrospective study
-
Medical management and costs associated with staphylococcus aureus (SA) bacteraemia in haemodialysis patients: A cost-of-illness study
-
Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation
-
Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving either cisplatin-based chemotherapy regimens or moderately emetogenic chemotherapy